FINWIRES · TerminalLIVE
FINWIRES

阿克蘇諾貝爾維持「買入」評級,貝倫貝格銀行指出,這是投資伊朗戰爭潛在降級的「好方法」。

By

-- 貝倫貝格銀行維持對阿克蘇諾貝爾(AKZA.AS)的「買入」評級,稱這家油漆和塗料公司的股票是伊朗衝突可能緩和的「良好投資標的」。 「油漆和塗料類股票通常在油價下跌時受益,因為原物料成本降低可以提高利潤率。歷史上,油價每下跌10美元/桶,阿克蘇諾貝爾的股價就會上漲3歐元/股。原油期貨曲線預測,未來兩年油價將下跌20美元/桶,至約75美元/桶。我們維持對阿克蘇諾歐元的「6歐元」報告在周二的目標下675歐元。 該研究公司也重點關注了這家荷蘭公司與美國塗料製造商艾仕得塗料系統公司(Axalta Coating Systems)合併的進展。分析師預計,後者將有助於阿克蘇諾貝爾改善成本管理,而成本管理一直是該公司先前「難以掌控」的領域。 在財務方面,分析師下調了對阿克蘇諾貝爾2026年至2028年每股收益(EPS)的預期,以反映銷量“略有下降”,尤其是在歐洲市場。相反,貝倫貝格銀行上調了對阿克蘇諾貝爾同期三年銷售額的預期。

Related Articles

Research

Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23

AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AES
Australia

Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell

Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%

$CMPX
Sectors

Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision

Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.

$GCM6$GLD